Bank of Montreal Can Grows Position in Qiagen N.V. $QGEN

Bank of Montreal Can raised its stake in shares of Qiagen N.V. (NYSE:QGEN) by 13.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 278,870 shares of the company’s stock after purchasing an additional 32,413 shares during the period. Bank of Montreal Can owned 0.13% of Qiagen worth $13,433,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Amalgamated Bank lifted its position in shares of Qiagen by 1.8% during the 2nd quarter. Amalgamated Bank now owns 11,751 shares of the company’s stock valued at $565,000 after buying an additional 209 shares in the last quarter. Atria Investments Inc lifted its holdings in Qiagen by 2.9% during the second quarter. Atria Investments Inc now owns 7,674 shares of the company’s stock valued at $369,000 after purchasing an additional 218 shares in the last quarter. ANTIPODES PARTNERS Ltd boosted its position in shares of Qiagen by 9.4% in the second quarter. ANTIPODES PARTNERS Ltd now owns 2,566 shares of the company’s stock worth $123,000 after purchasing an additional 221 shares during the period. Yousif Capital Management LLC increased its stake in shares of Qiagen by 3.7% in the second quarter. Yousif Capital Management LLC now owns 6,257 shares of the company’s stock worth $301,000 after purchasing an additional 222 shares in the last quarter. Finally, Truist Financial Corp increased its stake in shares of Qiagen by 7.7% in the second quarter. Truist Financial Corp now owns 6,170 shares of the company’s stock worth $297,000 after purchasing an additional 439 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

NYSE:QGEN opened at $43.54 on Friday. The business’s 50-day moving average is $46.46 and its 200 day moving average is $46.49. Qiagen N.V. has a 12 month low of $37.63 and a 12 month high of $51.88. The company has a market capitalization of $9.68 billion, a P/E ratio of 25.73, a P/E/G ratio of 2.48 and a beta of 0.64. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.03. The business had revenue of $533.00 million for the quarter, compared to the consensus estimate of $525.68 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.57 EPS. Qiagen has set its FY 2025 guidance at 2.380-2.380 EPS. Q4 2025 guidance at 0.600-0.600 EPS. On average, equities research analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on QGEN. UBS Group upped their target price on shares of Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Cowen reaffirmed a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th. Barclays set a $53.00 target price on Qiagen and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Wall Street Zen raised Qiagen from a “hold” rating to a “buy” rating in a report on Saturday, November 1st. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Qiagen in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Qiagen currently has a consensus rating of “Hold” and a consensus price target of $49.69.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.